PL398450A1 - Sposób otrzymywania nanoczastek polisacharydowych - Google Patents

Sposób otrzymywania nanoczastek polisacharydowych

Info

Publication number
PL398450A1
PL398450A1 PL398450A PL39845012A PL398450A1 PL 398450 A1 PL398450 A1 PL 398450A1 PL 398450 A PL398450 A PL 398450A PL 39845012 A PL39845012 A PL 39845012A PL 398450 A1 PL398450 A1 PL 398450A1
Authority
PL
Poland
Prior art keywords
aldehyde groups
bond
attachment
solution
water
Prior art date
Application number
PL398450A
Other languages
English (en)
Other versions
PL221351B1 (pl
Inventor
Tomasz Ciach
Iga Wasiak
Original Assignee
Politechnika Warszawska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Warszawska filed Critical Politechnika Warszawska
Priority to PL398450A priority Critical patent/PL221351B1/pl
Priority to EP13712947.4A priority patent/EP2825563B1/en
Priority to CA2866682A priority patent/CA2866682C/en
Priority to JP2015500386A priority patent/JP6470169B2/ja
Priority to PCT/PL2013/000030 priority patent/WO2013137755A1/en
Priority to CN201380014214.8A priority patent/CN104169305B/zh
Priority to BR112014022767-5A priority patent/BR112014022767B1/pt
Priority to IN1651MUN2014 priority patent/IN2014MN01651A/en
Priority to ES13712947T priority patent/ES2780387T3/es
Priority to RU2014133962A priority patent/RU2632019C2/ru
Priority to AU2013232850A priority patent/AU2013232850B2/en
Priority to MX2014010979A priority patent/MX369114B/es
Publication of PL398450A1 publication Critical patent/PL398450A1/pl
Priority to IL234572A priority patent/IL234572A/en
Priority to US14/485,309 priority patent/US10258579B2/en
Publication of PL221351B1 publication Critical patent/PL221351B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B1/00—Preparatory treatment of cellulose for making derivatives thereof, e.g. pre-treatment, pre-soaking, activation
    • C08B1/08—Alkali cellulose
    • C08B1/10—Apparatus for the preparation of alkali cellulose
    • C08B1/12—Steeping devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/02—Alkyl or cycloalkyl ethers
    • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
    • C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sposób otrzymywania nanoczastek z polisacharydów i ich pochodnych, poprzez ich specyficzne czesciowe utlenienie w celu wytworzenia grup aldehydowych i przylaczenie zwiazków zawierajacych grupe aminowa lub inna z wiazaniem R-NH2 reagujaca z grupami aldehydowymi, polega na tym, ze polisacharyd lub jego pochodna utlenia sie znana metoda z wytworzeniem grup aldehydowych do stopnia utlenienia od 0,1% do 80% pierscieni cukrowych, po czym do roztworu utlenionego polisacharydu w wodzie lub w mieszaninie wody z rozpuszczalnikiem organicznym, dodaje sie co najmniej jeden czynnik formujacy nanoczastki, którym jest organiczny zwiazek chemiczny majacy wiazanie R-NH2, który po przylaczeniu do grupy aldehydowej ma wlasciwosci hydrofobowe, oraz co najmniej jedna substancje czynna posiadajaca co najmniej jedno wiazanie R-NH2 lub N-H. Reakcje prowadzi sie przy pH roztworu od 1 do 9, w temperaturze od 10 do 100°C, przy czym sumaryczny molowy stosunek grup aminowych do aldehydowych wynosi od 20 do 0,5.
PL398450A 2012-03-14 2012-03-14 Sposób otrzymywania nanocząstek polisacharydowych PL221351B1 (pl)

Priority Applications (14)

Application Number Priority Date Filing Date Title
PL398450A PL221351B1 (pl) 2012-03-14 2012-03-14 Sposób otrzymywania nanocząstek polisacharydowych
IN1651MUN2014 IN2014MN01651A (pl) 2012-03-14 2013-03-12
ES13712947T ES2780387T3 (es) 2012-03-14 2013-03-12 Procedimiento para la preparación de nanopartículas de polisacáridos
JP2015500386A JP6470169B2 (ja) 2012-03-14 2013-03-12 多糖ナノ粒子の調製方法
PCT/PL2013/000030 WO2013137755A1 (en) 2012-03-14 2013-03-12 Process for the preparation of polysaccharide nanoparticles
CN201380014214.8A CN104169305B (zh) 2012-03-14 2013-03-12 制备多糖纳米粒的方法
BR112014022767-5A BR112014022767B1 (pt) 2012-03-14 2013-03-12 Processo para a preparação de nanopartículas de polissacarídeos e nanopartículas assim obtidas
EP13712947.4A EP2825563B1 (en) 2012-03-14 2013-03-12 Process for the preparation of polysaccharide nanoparticles
CA2866682A CA2866682C (en) 2012-03-14 2013-03-12 Process for the preparation of polysaccharide nanoparticles
RU2014133962A RU2632019C2 (ru) 2012-03-14 2013-03-12 Способ получения наночастиц полисахаридов
AU2013232850A AU2013232850B2 (en) 2012-03-14 2013-03-12 Process for the preparation of polysaccharide nanoparticles
MX2014010979A MX369114B (es) 2012-03-14 2013-03-12 Proceso para la preparación de nanopartículas de polisacáridos.
IL234572A IL234572A (en) 2012-03-14 2014-09-10 Process for making polysaccharide nanoparticles
US14/485,309 US10258579B2 (en) 2012-03-14 2014-09-12 Process for the preparation of polysaccharide nanoparticles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL398450A PL221351B1 (pl) 2012-03-14 2012-03-14 Sposób otrzymywania nanocząstek polisacharydowych

Publications (2)

Publication Number Publication Date
PL398450A1 true PL398450A1 (pl) 2013-09-16
PL221351B1 PL221351B1 (pl) 2016-03-31

Family

ID=48014274

Family Applications (1)

Application Number Title Priority Date Filing Date
PL398450A PL221351B1 (pl) 2012-03-14 2012-03-14 Sposób otrzymywania nanocząstek polisacharydowych

Country Status (14)

Country Link
US (1) US10258579B2 (pl)
EP (1) EP2825563B1 (pl)
JP (1) JP6470169B2 (pl)
CN (1) CN104169305B (pl)
AU (1) AU2013232850B2 (pl)
BR (1) BR112014022767B1 (pl)
CA (1) CA2866682C (pl)
ES (1) ES2780387T3 (pl)
IL (1) IL234572A (pl)
IN (1) IN2014MN01651A (pl)
MX (1) MX369114B (pl)
PL (1) PL221351B1 (pl)
RU (1) RU2632019C2 (pl)
WO (1) WO2013137755A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016093352A1 (ja) * 2014-12-12 2016-06-16 日本化薬株式会社 核酸代謝拮抗剤が結合した多分岐化合物
PL3491092T3 (pl) * 2016-08-01 2024-01-29 Integrity Bio-Chemicals, Llc Biopolimery do kontroli unoszenia się pyłów
US10736964B2 (en) * 2017-05-01 2020-08-11 China Medical University Immunomagnetic nanocapsule and kit for treating cancer
CN107446054B (zh) * 2017-08-11 2021-05-18 武汉理工大学 一种生物质基纳米粒子及其制备方法和应用
PL424773A1 (pl) * 2018-03-06 2019-09-09 Nanovelos Spółka Akcyjna Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów
CN108676181B (zh) * 2018-05-30 2022-05-17 江西师范大学 通过二醛基纤维素制备纤维素纳米颗粒的方法
CN108553448A (zh) * 2018-05-30 2018-09-21 江西师范大学 一种pH响应的药物缓释纤维素纳米颗粒的制备方法
PL240772B1 (pl) 2018-06-11 2022-06-06 Nanothea Spolka Akcyjna Sposób wytwarzania nanocząstek polimerowych chelatujących izotopy promieniotwórcze do zastosowania w diagnostyce i terapii
CN112353781B (zh) * 2020-11-12 2022-08-19 云南开放大学 一种药物载体空心纳米球的制备方法
CN112516310B (zh) * 2020-12-11 2022-11-29 武汉理工大学 一种肿瘤酸环境响应的纳米前药的制备方法及其应用
CN112830979A (zh) * 2021-01-15 2021-05-25 江南大学 一种改性黄原胶及其制备方法与应用
CN113800501B (zh) * 2021-10-08 2023-04-18 山西大学 一种用于检测pH和精氨酸的橙红色荧光碳点的制备方法及其应用
WO2023092208A1 (pt) * 2021-11-25 2023-06-01 Universidade Estadual De Campinas Processo de obtenção de solução polimérica injetável fotoreticulável, solução polimérica injetável fotoreticulável e seus usos
CN115463262B (zh) * 2022-08-11 2024-06-04 南方医科大学第五附属医院 一种水凝胶复合修复补片及其制备方法与应用
CN117898426A (zh) * 2023-12-05 2024-04-19 江苏蓝果临床营养科技有限公司 一种调节肠道功能紊乱的纳米颗粒及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU825542A1 (ru) * 1979-04-04 1981-04-30 Inst Orch Chimii Aka Способ получения n-производных полисахаридов 1
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4693912A (en) * 1985-02-28 1987-09-15 Technicon Instruments Corporation Lyophilization of reagent-coated particles
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
JPS62221637A (ja) * 1986-03-24 1987-09-29 Green Cross Corp:The 制癌剤−抗体複合体の製造方法
JPS62283101A (ja) * 1986-05-30 1987-12-09 Green Cross Corp:The 制癌作用物質複合体の製造方法
JPS63264427A (ja) * 1986-12-17 1988-11-01 Green Cross Corp:The 制癌作用物質複合体
JPH01190636A (ja) * 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
EP0999222A1 (en) 1998-11-02 2000-05-10 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Carbohydrate oxidation products
US7939105B2 (en) * 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
CA2412582A1 (en) 2000-06-29 2002-01-03 Daiichi Pharmaceutical Co., Ltd. Dds compound and process for the preparation thereof
DE10129369C1 (de) 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Wasserlösliches, einen Aminozucker aufweisendes Antibiotikum in Form eines Pol ysaccharid-Konjugats
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
JP2005535604A (ja) * 2002-06-03 2005-11-24 アルニス バイオサイエンシーズ， インコーポレイテッド 治療剤を含むポリマーナノ物品
KR100578382B1 (ko) * 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
KR101536897B1 (ko) * 2005-05-27 2015-07-15 로이어 바이오메디칼 인코포레이티드 생체재흡수성 중합체 매트릭스 및 이의 제조방법과 사용방법
EP1937304A2 (en) 2005-08-24 2008-07-02 Novartis Vaccines and Diagnostics S.r.l. Zwitterionization of capsular saccharides
CN101273066B (zh) * 2005-09-09 2013-10-16 郑特来 用于递送抗癌剂的水溶性壳聚糖纳米颗粒及其制备方法
WO2007034495A2 (en) * 2005-09-22 2007-03-29 Hadasit Medical Research Services & Development Limited Dextran and arabinogalactan conjugates of therapeutically active compounds
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
CN105833337B (zh) * 2008-11-19 2020-01-21 阿克塔马克斯手术器材有限责任公司 纤维组织封合剂及其使用方法
CZ302503B6 (cs) * 2009-12-11 2011-06-22 Contipro C A.S. Zpusob prípravy derivátu kyseliny hyaluronové oxidovaného v poloze 6 glukosaminové cásti polysacharidu selektivne na aldehyd a zpusob jeho modifikace
EP2590680A1 (en) 2010-07-09 2013-05-15 Fresenius Kabi Deutschland GmbH Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation

Also Published As

Publication number Publication date
US20150072946A1 (en) 2015-03-12
MX2014010979A (es) 2015-02-24
BR112014022767A2 (pl) 2017-10-03
WO2013137755A1 (en) 2013-09-19
EP2825563A1 (en) 2015-01-21
IL234572A (en) 2017-01-31
MX369114B (es) 2019-10-29
ES2780387T3 (es) 2020-08-25
CN104169305A (zh) 2014-11-26
RU2014133962A (ru) 2016-03-20
US10258579B2 (en) 2019-04-16
CA2866682C (en) 2016-05-17
AU2013232850A1 (en) 2014-09-11
JP6470169B2 (ja) 2019-02-13
CA2866682A1 (en) 2013-09-19
RU2632019C2 (ru) 2017-10-02
CN104169305B (zh) 2016-07-27
BR112014022767B1 (pt) 2021-08-31
PL221351B1 (pl) 2016-03-31
JP2015514059A (ja) 2015-05-18
EP2825563B1 (en) 2020-02-05
IN2014MN01651A (pl) 2015-05-29
AU2013232850B2 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
CO6361852A2 (es) Derivados de hidroximoil-tetrazol fungicidas
MX369114B (es) Proceso para la preparación de nanopartículas de polisacáridos.
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
CL2015001386A1 (es) Composición de fertilizantes
MX2016006841A (es) Nuevos compuestos pesticidas y usos.
BRPI0920145B8 (pt) compostos de tioamida, método de produção e método de uso dos mesmos
PA8854001A1 (es) Compuestos novedosos como ligandos de receptores de canabinoides
CY1119665T1 (el) Ζιζανιοκτονος συνθεση σε υδατικο εναιωρημα
MA28685B1 (fr) Derives de la quinazolinone, antagonistes de la vanilloide
PL403902A1 (pl) Preparat krzemowy o właściwościach stymulujących rozwój roślin, sposób wytwarzania preparatu krzemowego stymulującego rozwój roślin i jego zastosowanie
CO6361853A2 (es) Derivados de hidroximoil-tetrazol fungicidas
EP1995249A4 (en) CAMPTOTHECIN DERIVATIVES AND THEIR USE
MX2013007726A (es) Derivados de 2-metoxi-piridin-4-ilo.
AR106195A1 (es) Proceso para la preparación de ácido 1-(4-metanosulfonil-2-trifluorometil-bencil)-2-metil-1h-pirrolo[2,3-b]piridin-3-il-acético e intermediarios de dicha síntesis
UA110933C2 (uk) Композиція для лікування есенціальної тромбоцитемії
UY30235A1 (es) Inhibidores de la adenilato ciclasa soluble
PL404820A1 (pl) Sposób otrzymywania nanocząstek hydroksyapatytowych
PL413441A1 (pl) Sposób wytwarzania zawiesiny nanocząstek srebra i zawiesina nanocząstek srebra
PL413493A1 (pl) Czwartorzędowe sole difenokonazolu z anionem nieorganicznym, sposób ich otrzymywania oraz zastosowania jako fungicydów
PL407817A1 (pl) Sposób otrzymywania nanocząstek tlenku miedzi (I)
PL415546A1 (pl) Sposób uzyskiwania stabilnych suspensji nanocząstek srebra o dodatnim ładunku powierzchniowym
PL404282A1 (pl) Sposób wytwarzania antypirenu o zwiększonej gęstości nasypowej do poliamidu
PL405597A1 (pl) Sposób unieruchamiania respirabilnych włókien azbestowych
PL415545A1 (pl) Sposób wytwarzania stabilnych suspensji nanocząstek srebra o dodatnim ładunku powierzchniowym
UY31852A (es) Derivados y carboxamidas n sustituidas del ácido 3-oxo-2-(2-piridin-2-iletil)-n-1-h-isoindol-1-conteniéndolos y aplicaciones